NO970369L - Identifikasjon av en human cytomegalovirus-genregion involvert i nedregulering av MHC-klasse 1-tungkjede-ekspresjon - Google Patents

Identifikasjon av en human cytomegalovirus-genregion involvert i nedregulering av MHC-klasse 1-tungkjede-ekspresjon

Info

Publication number
NO970369L
NO970369L NO970369A NO970369A NO970369L NO 970369 L NO970369 L NO 970369L NO 970369 A NO970369 A NO 970369A NO 970369 A NO970369 A NO 970369A NO 970369 L NO970369 L NO 970369L
Authority
NO
Norway
Prior art keywords
heavy chain
downregulation
mhc class
human cytomegalovirus
identification
Prior art date
Application number
NO970369A
Other languages
English (en)
Norwegian (no)
Other versions
NO970369D0 (no
Inventor
Ann E Campbell
Thomas R Jones
Original Assignee
American Cyanamid Co
Ann E Campbell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co, Ann E Campbell filed Critical American Cyanamid Co
Publication of NO970369D0 publication Critical patent/NO970369D0/no
Publication of NO970369L publication Critical patent/NO970369L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C07K14/045—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161—Methods of inactivation or attenuation
    • C12N2710/16162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO970369A 1994-07-29 1997-01-28 Identifikasjon av en human cytomegalovirus-genregion involvert i nedregulering av MHC-klasse 1-tungkjede-ekspresjon NO970369L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/282,696 US5846806A (en) 1994-07-29 1994-07-29 Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
PCT/US1995/009607 WO1996004383A1 (fr) 1994-07-29 1995-07-28 Identification d'une region du gene du cytomegalovirus humain (hcmv), jouant un role dans la retroregulation de l'expression des chaines lourdes des mhc de classe i

Publications (2)

Publication Number Publication Date
NO970369D0 NO970369D0 (no) 1997-01-28
NO970369L true NO970369L (no) 1997-03-21

Family

ID=23082718

Family Applications (2)

Application Number Title Priority Date Filing Date
NO970369A NO970369L (no) 1994-07-29 1997-01-28 Identifikasjon av en human cytomegalovirus-genregion involvert i nedregulering av MHC-klasse 1-tungkjede-ekspresjon
NO970370A NO970370L (no) 1994-07-29 1997-01-28 Identifikasjon av et human cytomegalovirusgen involvert i nedregulering av MHC-klasse 1-tungkjede-ekspresjon

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO970370A NO970370L (no) 1994-07-29 1997-01-28 Identifikasjon av et human cytomegalovirusgen involvert i nedregulering av MHC-klasse 1-tungkjede-ekspresjon

Country Status (11)

Country Link
US (6) US5846806A (fr)
EP (2) EP0775209A1 (fr)
JP (2) JP4036469B2 (fr)
KR (2) KR970704883A (fr)
AU (2) AU709552B2 (fr)
CA (3) CA2195668C (fr)
FI (2) FI970352A (fr)
MX (1) MX9700676A (fr)
NO (2) NO970369L (fr)
NZ (2) NZ290718A (fr)
WO (2) WO1996004383A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032605A1 (fr) * 1996-03-08 1997-09-12 Massachusetts Institute Of Technology Acides nucleiques de cytomegalovirus codant pour des proteines ayant une liaison mhc de classe i normale ou modifiee et utilises dans le traitement de certaines maladies
AU730351B2 (en) * 1996-07-31 2001-03-08 Ortho-Mcneil Pharmaceutical, Inc. Identification of human cytomegalovirus genes involved in down-regulation of MHC class I heavy chain expression
WO1998031813A1 (fr) * 1997-01-17 1998-07-23 Roche Diagnostics Gmbh Inhibiteur de la presentation d'antigenes par des molecules de mhc de classe i
WO1998047914A2 (fr) * 1997-04-18 1998-10-29 Roche Diagnostics Gmbh Gene us6 issu du cytomegalovirus humain
JP2002508976A (ja) * 1998-01-14 2002-03-26 ヒューマン ジーン セラピー リサーチ インスティテュート 遺伝子療法において使用するための、免疫原性が低下したヌクレオチド発現システム
US6100008A (en) * 1998-09-14 2000-08-08 Ppg Industries Ohio, Inc. Positive photoresist with improved contrast ratio and photospeed
WO2000046361A1 (fr) * 1999-02-02 2000-08-10 Oregon Health Sciences University Inhibition du chemin de presentation de l'antigene du complexe majeur d'histocompatibilite de classe ii et presentation aux cellules cd4+
AU2001288682A1 (en) * 2000-08-30 2002-03-13 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
US6740324B2 (en) * 2001-02-02 2004-05-25 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
US20030118568A1 (en) * 2001-12-18 2003-06-26 Board Of Trustees Of The University Of Arkansas Viral stealth technology to prevent T cell-mediated rejection of xenografts
US20040228842A1 (en) * 2003-02-27 2004-11-18 Shan Lu Compositions and methods for cytomegalovirus treatment
KR20050093003A (ko) * 2004-03-17 2005-09-23 이재본 직류형 마이크로 터빈 발전기
EP2114991A1 (fr) 2007-02-07 2009-11-11 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Antigenes recombinants du cytomegalovirus humain (hcmv)
CA2705461A1 (fr) * 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Vaccins contre plusiseurs sous-types de virus de l'influenza
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
LT2569436T (lt) 2010-05-14 2018-03-12 Oregon Health & Science University Rekombinantiniai žcmv ir hcmv vektoriai ir jų panaudojimas
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University CMV glycoproteins and recombinant vectors
CA2904001C (fr) 2013-03-05 2021-07-13 Oregon Health & Science University Vecteurs cytomegalovirus permettant la commande du ciblage de lymphocyte t
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
WO2016011293A1 (fr) 2014-07-16 2016-01-21 Oregon Health & Science University Cytomégalovirus humain comprenant des antigènes exogènes
CN108064304A (zh) 2015-02-10 2018-05-22 俄勒冈健康与科学大学 可用于产生非典型cd8+ t细胞应答的方法和组合物
EP3377636A4 (fr) 2015-11-20 2019-11-06 Oregon Health & Science University Vecteurs cmv comprenant des éléments de reconnaissance des microarn
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN109843321A (zh) 2016-06-22 2019-06-04 国际艾滋病疫苗行动组织公司 作为结核病疫苗的重组巨细胞病毒载体
CN110036112B (zh) 2016-10-18 2024-05-10 俄勒冈健康与科学大学 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体
US11638749B2 (en) 2017-10-17 2023-05-02 International Aids Vaccine Initiative, Inc. Tuberculosis antigen cassettes
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TW202413391A (zh) 2020-06-21 2024-04-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058598A (en) * 1974-10-18 1977-11-15 Harold Stern Cytomegalovirus attenuation method and vaccine
US4689225A (en) * 1984-11-02 1987-08-25 Institut Merieux Vaccine for cytomegalovirus
US4877612A (en) * 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
US4877737A (en) * 1985-09-06 1989-10-31 Prutech Research And Development Partnership Attenuated pseudorabies virus which has a deletion in at least a portion of a repeat sequence and vaccine containing same
US5273876A (en) * 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
ATE118822T1 (de) * 1987-06-26 1995-03-15 Syntro Corp Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
AU3550489A (en) * 1988-05-09 1989-11-29 Children's Hospital Incorporated, The Vectors encoding hcmv glycoprotein and expression products
SG49046A1 (en) * 1991-07-05 1998-05-18 American Cyanamid Co Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegaloverirus

Also Published As

Publication number Publication date
CA2195668A1 (fr) 1996-02-15
WO1996004383A1 (fr) 1996-02-15
AU3274595A (en) 1996-03-04
NO970370D0 (no) 1997-01-28
KR970704883A (ko) 1997-09-06
KR970704884A (ko) 1997-09-06
CA2195668C (fr) 2004-09-21
AU708983B2 (en) 1999-08-19
NO970370L (no) 1997-03-24
CA2328638A1 (fr) 1996-02-15
US5753476A (en) 1998-05-19
CA2196207C (fr) 2002-04-30
US5843458A (en) 1998-12-01
MX9700710A (es) 1997-09-30
EP0772681A1 (fr) 1997-05-14
US5846806A (en) 1998-12-08
FI970351A0 (fi) 1997-01-28
CA2196207A1 (fr) 1996-02-15
NZ291571A (en) 1999-01-28
US5908780A (en) 1999-06-01
JPH10506268A (ja) 1998-06-23
AU709552B2 (en) 1999-09-02
NZ290718A (en) 1999-03-29
US5720957A (en) 1998-02-24
FI970352A0 (fi) 1997-01-28
JPH10503378A (ja) 1998-03-31
WO1996004384A1 (fr) 1996-02-15
US5906935A (en) 1999-05-25
AU3153595A (en) 1996-03-04
EP0775209A1 (fr) 1997-05-28
NO970369D0 (no) 1997-01-28
FI970351A (fi) 1997-01-28
FI970352A (fi) 1997-01-28
MX9700676A (es) 1997-04-30
JP4036469B2 (ja) 2008-01-23

Similar Documents

Publication Publication Date Title
NO970369L (no) Identifikasjon av en human cytomegalovirus-genregion involvert i nedregulering av MHC-klasse 1-tungkjede-ekspresjon
Shemer et al. Structure of the imprinted mouse Snrpn gene and establishment of its parental-specific methylation pattern
Epstein et al. Expression of H‐Y antigen on preimplantation mouse embryos
GR3025961T3 (en) Amplification of human mdm2 gene in human tumors.
DE69738709D1 (de) Herpes simplex virusstaemme
EA199800566A1 (ru) Аденовирусный вектор (варианты), способ его получения, применение, репликационно-компетентное не содержащее аденовирус потомство, способ повышения размножения в комплементирующей клеточной линии аденовирусного вектора, способ генетической модификации клетки, композиция, клетка-хозяин, способ тестирования токсичности аденовирусного вектора, способ тестирования экспрессии чужеродного гена или гена-пассажира аденовирусного вектора
TW369564B (en) Methods for reducing inhibition of nucleic acid amplification reactions
Perng et al. A herpes simplex virus type 1 latency-associated transcript mutant with increased virulence and reduced spontaneous reactivation
Furukawa et al. Animal models of spontaneous and drug-induced cutaneous lupus erythematosus
MX9705039A (es) Genes y proteinas de muerte celular programada.
WO1998037185A3 (fr) Vecteurs pour expression genique regulee
WO1998004709A3 (fr) Proteine icp4 du virus de l'herpes simplex en tant qu'inhibiteur de l'apoptose
AU5318496A (en) Adenovirus vectors for gene therapy
ATE288483T1 (de) Nicht-verbreitendes lebendes herpesvirusvakzin
Simeonov et al. T cell subset-selective IL2RA enhancers shape autoimmune diabetes risk
ATE235814T1 (de) Behandlung von roten blutzellen zur inaktivierung von virien durch verwendung von pathalocyanine und rotlicht
Jefferies Effects of continuous and fractionated doses of gamma radiation on the survival and fertility of Sitophilus granarius (L.)
MX9605941A (es) Procedimiento para introducir material extraño en celulas eucarioticas superiores.
DK0741791T3 (da) CD69-Tanskriptionsregulerende elementer
Lobitz et al. Giemsa banding pattern of a heritable 1q+ variant chromosome: a possible partial duplication.
Shipp Stage-specific alterations in ectodermal segment formation of Mysidopsis bahia (Crustacea, Malacostraca, Peracarida, Mysidacea) caused by macromolecular inhibitors and centrifugation.
Løvhaug et al. Regulation of bone marrow cell growth in diffusion chambers: the effect of granulocyte extracts
Bootsma Defective DNA repair and cancer
Biswal et al. Regulation of viral and cellular genes in a human neuroblastoma cell line latently infected with herpes simplex virus type 2
Huang et al. Expression of bcl-2 in human ocular surface epithelia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application